Cullinan Oncology LLC (CGEM)

Cullinan Oncology LLC (CGEM) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $961M; returns 1 day -3.7%, 1 week +11.1%, 1 year +85.9%.

Cullinan Therapeutics, Inc. (CGEM) is a clinical-stage biopharmaceutical company focused on developing potential first-in-class or best-in-class therapies for autoimmune diseases and cancer. As of December 31, 2025, Cullinan reported preliminary cash, cash equivalents, and investments of $439 million, which is projected to fund operations into 2029.

Groups CGEM belongs to

• Biotechnology
• Clinical Stage Biotech
• Oncology
• Autoimmune Diseases
• Healthcare
• Biopharmaceutical
• Cancer Therapeutics
• Clinical Stage
• Bispecific Antibodies
• Life Sciences

CGEM financial model: income statement, cash flow and balance sheet